Genmab A (GMAB) Enterprise Value (2023 - 2025)
Historic Enterprise Value for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to -$1.7 billion.
- Genmab A's Enterprise Value rose 2257.34% to -$1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.7 billion, marking a year-over-year increase of 2257.34%. This contributed to the annual value of -$1.7 billion for FY2025, which is 2257.34% up from last year.
- As of Q4 2025, Genmab A's Enterprise Value stood at -$1.7 billion, which was up 2257.34% from -$1.9 billion recorded in Q3 2025.
- In the past 5 years, Genmab A's Enterprise Value ranged from a high of -$624.0 million in Q2 2024 and a low of -$2.4 billion during Q4 2023
- Over the past 3 years, Genmab A's median Enterprise Value value was -$1.7 billion (recorded in 2025), while the average stood at -$1.7 billion.
- Data for Genmab A's Enterprise Value shows a peak YoY increase of 2472.31% (in 2025) and a maximum YoY decrease of 12724.36% (in 2025) over the last 5 years.
- Genmab A's Enterprise Value (Quarter) stood at -$2.4 billion in 2023, then rose by 7.86% to -$2.2 billion in 2024, then grew by 22.57% to -$1.7 billion in 2025.
- Its Enterprise Value was -$1.7 billion in Q4 2025, compared to -$1.9 billion in Q3 2025 and -$1.4 billion in Q2 2025.